Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.
Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.


RARE DISEASE
Pneumonia caused by Pseudomonas aeruginosa infection
Pneumonia caused by Pseudomonas aeruginosa infection
Pneumonia caused by Pseudomonas aeruginosa infection
Drug discovery
8
drugs
With orphan designations
Rare respiratory disease
Pneumonia caused by Pseudomonas aeruginosa infection
Overview
Pseudomonas aeruginosa pneumonia is a severe infection primarily associated with healthcare settings, particularly ventilator-associated pneumonia (VAP) in ICU patients. It accounts for ~20% of ICU-acquired pneumonias and carries high mortality (28–42.8%) due to intrinsic antibiotic resistance and frequent multidrug-resistant (MDR) strains. Community-acquired cases are rare (0.9–4.2%) but linked to chronic lung diseases like COPD or bronchiectasis [1][2][4][6][12].
Population
High-risk groups: ICU patients on mechanical ventilation, immunosuppressed individuals (neutropenia, cystic fibrosis), and those with structural lung disease (COPD, bronchiectasis) [1][6][12][16].
Prior P. aeruginosa colonization, recent hospitalization, or antibiotic use increases susceptibility [4][12][19].
Burden
Mortality: 30-day mortality reaches 28% in CAP and 42.8% in VAP; MDR strains increase mortality risk [2][12][17].
Economic impact: Hospital-acquired cases incur €19,000+ additional costs due to prolonged ICU stays [9].
Antibiotic resistance: MDR strains cause 33% of VAP cases globally, with resistance rates exceeding 80% in high-risk regions [12][14].
Therapies
Empirical therapy: Novel β-lactam/β-lactamase inhibitors (ceftolozane-tazobactam, ceftazidime-avibactam) or cefiderocol for suspected MDR strains [3][8][13].
Definitive therapy: Guided by susceptibility testing; avoid unnecessary antipseudomonal drugs in low-risk CAP cases to reduce resistance [2][3][13].
Adjunctive approaches: Investigational therapies (phages, vaccines) for refractory MDR/XDR infections [8][14].
Categories: rare respiratory diseases
Research Papers
939 drug discovery papers about Pneumonia caused by Pseudomonas aeruginosa infection, with 3 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
939 drug discovery papers about Pneumonia caused by Pseudomonas aeruginosa infection, with 3 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
categories:
Small molecules
small molecules
2026-09-30 | Qiguiyin Formula Combined with Fosfomycin Alleviates Lung Injury Induced by Pseudomonas Aeruginosa Infection via the Gut-Lung Axis.
Multidrug-resistant Pseudomonas aeruginosa (MDR-PA) pneumonia is characterized by limited clinical antimicrobial options, severe inflammatory damage and high mortality. MDR-PA infection can trigger intestinal microecological imbalance and immune disorders. Qiguiyin Formula is a classic traditional Chinese medicinal compound clinically applied for infections caused by drug-resistant Pseudomonas aeruginosa. This study aimed to clarify the relationship between intestinal flora dysbiosis induced by MDR-PA infection and pathological injuries in the lung and intestine, as well as evaluate the therapeutic potential of Qiguiyin Formula combined with fosfomycin, and further elaborate its mechanism of action from the perspective of the gut-lung axis. Mouse models of multidrug-resistant Pseudomonas aeruginosa (MDR-PA) infection and corresponding intervention models treated with Qiguiyin Formula and fosfomycin were established. HE staining, RT-qPCR, chemiluminescence immunoassay, 16S rRNA sequencing and non-targeted metabolomics analysis were applied to assess immune damage and gut microbiota structure in lung and intestinal tissues. MDR-PA infection leads to severe imbalance of the intestinal flora, manifested by an increase in pathogenic bacteria (Escherichia coli, Shigella) and a significant decrease in beneficial bacteria (Lactobacillus, Bifidobacterium), and an increase in inflammatory metabolites such as arachidonic acid, linoleic acid, and α-linolenic acid, causing disorders in lipid metabolism pathways and MAPK signaling pathways. The HE staining results show that MDR-PA infection damages the lung structure, triggers alveolar inflammation, downregulates the expression of ZO-1, damages the colonic barrier, and induces a pro-inflammatory cytokine storm, resulting in a high mortality rate. In terms of treatment, the intervention of the Qiguiyin Formula combined with fosfomycin demonstrates the advantages of a synergistic effect: improving the imbalance of intestinal flora, reshaping core metabolic pathways such as lipids, amino acids, and arginine, repairing the integrity of the intestinal barrier, and inhibiting the expression of inflammatory factors. MDR-PA infection disrupts intestinal flora homeostasis and induces metabolic disorders. The combined use of Qiguiyin Formula and fosfomycin alleviates pulmonary injury by improves the diversity and stability of the intestinal microbiota, corrects the abnormal activation of lipid and amino acid metabolic pathways, and restores the normal metabolic signals of the microbiota, thereby inhibiting lung damage.
2026-09-15 | A Four-Center Study on the Activity of Aztreonam and Aztreonam-Avibactam Combination Against Clinical Isolates of Gram-Negative Bacilli Producing Representatives of Ambler Class A, B, C or D β-Lactamases.
We aimed to investigate the activity of aztreonam and aztreonam-avibactam combination against gram-negative bacilli producing different types of β-lactamases. Activity of aztreonam and aztreonam-avibactam against 166 isolates (33 AmpC-producing, 33 ESBL-producing, 66 carbapenemase-producing Enterobacterales, 34 metallo-β-lactamase-producing P. aeruginosa) from four centers in Türkiye was determined using gradient diffusion method. Aztreonam susceptibility rates among AmpC-producing, ESBL-producing and carbapenemase-producing Enterobacterales were 75.8%, 3% and 6.1%, respectively. All AmpC-producing or ESBL-producing Enterobacterales were susceptible to aztreonam-avibactam. ESBL-producing K. pneumoniae had significantly higher aztreonam-avibactam MICs compared with ESBL-producing E. coli. K. pneumoniae carrying blaCTX-M + blaSHV + blaTEM had significantly higher aztreonam-avibactam MICs when compared to those carrying only blaCTX-M. Aztreonam-avibactam susceptibility rate among carbapenemase-producing K. pneumoniae (100%) was significantly higher than that observed for carbapenemase-producing E. coli (65%). Metallo-β-lactamase-producing P. aeruginosa had significantly higher aztreonam-avibactam MICs (MIC50/90: 16/96 mg/L) when compared to metallo-β-lactamase-producing Enterobacterales (MIC50/90: 0.19/8 mg/L). Aztreonam-avibactam may be an option for treatment of infections caused by ESBL-producing or AmpC-producing K. pneumoniae, E. coli and carbapenemase-producing K. pneumoniae. However, aztreonam-avibactam resistance may be encountered in a considerable portion of carbapenem-resistant E. coli isolates. High aztreonam-avibactam MIC values suggest limited in vitro activity of aztreonam-avibactam against MBL-producing P. aeruginosa isolates in this collection.
2026-09-09 | Sorafenib analogues exhibit dual Colistin-potentiating and anti-MRSA activity.
In response to the antimicrobial resistance (AMR) global health crisis, physicians have been forced to employ antibiotics of last resort such as colistin, which had previously been removed from clinics due to toxicity concerns. The increase in colistin usage has in turn resulted in the increased incidence of colistin-resistant isolates, making novel therapeutic options for infections caused by these pathogens a priority. We previously reported that sorafenib, a eukaryotic kinase inhibitor, is a colistin adjuvant, augmenting colistin activity against colistin-resistant Klebsiella pneumoniae and Acinetobacter baumannii. Herein, we describe the generation of a library of analogues based upon the sorafenib scaffold, lead compounds from which sensitize colistin-resistant K. pneumoniae, A. baumannii, and Pseudomonas aeruginosa to colistin, and exhibit reduced cytotoxicity compared to sorafenib. We also describe the standalone antimicrobial activity of these sorafenib analogues against methicillin-resistant Staphylococcus aureus (MRSA). Lead compound NDM-773 lowers the colistin minimum inhibitory concentration (MIC) against K. pneumoniae B9 from 512 μg mL-1 to 2 μg mL-1 at 1.5 μM, against A. baumannii 4106 from 1024 μg mL-1 to 1 μg mL-1 at 4 μM, and against P. aeruginosa TRPA162 from 8192 μg mL-1 to ≤0.125 μg mL-1 at 7.5 μM. NDM-773 acts as a standalone antibiotic against MRSA with an MIC of 0.781 μM (0.398 μg mL-1) and a frequency of mutation rate of <10-11 against MRSA BAA-1556. NDM-773 exhibits over three-fold reduction in HepG2 toxicity compared to sorafenib, and has therapeutic indices (TIs) up to 35.6 as a colistin adjuvant, and 68.4 as an MRSA antibiotic.
2026-08-27 | SEVERE AND RECURRENT PSEUDOMONAS AERUGINOSA INFECTIONS IN CRITICALLY ILL PATIENTS: A CASE SERIES OF PNEUMONIA, SEPSIS, SEPTIC PULMONARY EMBOLI, AND DIABETIC KETOACIDOSIS
Background: Pseudomonas aeruginosa is an important opportunistic pathogen associated with severe healthcare-associatedinfections, particularly among critically ill patients. It can cause pneumonia, bloodstream infection, sepsis, abscesses, and othermetastatic complications. Treatment can be challenging because of its intrinsic and acquired antimicrobial resistancemechanisms. The clinical course may be further complicated by diabetes mellitus, diabetic ketoacidosis (DKA), acuterespiratory distress syndrome (ARDS), prolonged mechanical ventilation, and recurrent infection. Case presentations: Wedescribe three critically ill male patients with severe P. aeruginosa-associated infections requiring intensive care management.Case 1 was a 36-year-old man with newly diagnosed diabetes mellitus and DKA who developed severe P. aeruginosapneumonia complicated by ARDS, septic shock, acute kidney injury, and prolonged mechanical ventilation. Blood andendotracheal aspirate cultures repeatedly yielded P. aeruginosa, reported as susceptible to meropenem and resistant to colistinand polymyxin-B. After initial recovery and discharge, he was readmitted with fever and a left foot abscess. CT pulmonaryangiography demonstrated multiple pulmonary nodules and cavitary lesions suggestive of septic pulmonary emboli. Bloodand pus cultures again yielded P. aeruginosa. Source control was achieved by incision and drainage, and antimicrobial therapywas escalated to ceftazidime-avibactam.Case 2 was a 27-year-old man who presented with high-grade fever, right knee pain, jaundice, severe hypoxemia, andrespiratory failure. He required intubation, mechanical ventilation, prone positioning, and intensive care treatment. Bloodculture initially demonstrated Gram-negative bacilli subsequently identified as P. aeruginosa. He improved followingtreatment but was readmitted with recurrent fever, severe tachycardia, dyspnea, and persistent right knee symptoms. Theavailable records suggest possible musculoskeletal involvement; however, definitive microbiological confirmation fromsynovial fluid or other joint specimens was not available in the source material. Case 3 was a 25-year-old man with diabetesmellitus who presented with severe hyperglycemia, positive urine ketones, high-grade fever, profound hypoxemia, and clinicalfeatures of severe infection. He required emergency intubation, mechanical ventilation, intravenous insulin, fluid resuscitation,and broad-spectrum antimicrobial therapy. Blood and endotracheal cultures subsequently demonstrated P. aeruginosa, reportedas susceptible to meropenem and resistant to colistin. Following culture-directed antimicrobial therapy and metaboliccorrection, he improved and was successfully extubated. Conclusion: These cases demonstrate the heterogeneous andpotentially severe manifestations of P. aeruginosa infection in critically ill patients. Recurrent bacteremia should promptcareful reassessment for persistent or metastatic sources of infection and consideration of definitive source control. Severeinfection may coexist with or precipitate DKA and ARDS, requiring coordinated antimicrobial, metabolic, respiratory, andcritical-care management. Repeated microbiological assessment and antimicrobial susceptibility testing are essential forguiding therapy.
2026-08-27 | Real-World Use of Cefiderocol for Multidrug-Resistant Gram-Negative Infections in Critically Ill ICU Patients: A Single-Center Case Series.
Carbapenem-resistant Gram-negative (CR-GN) infections are associated with high mortality in intensive care units (ICUs), with limited therapeutic options. We aimed to evaluate microbiological and clinical outcomes associated with cefiderocol in critically ill patients with multidrug-resistant (MDR) Gram-negative infections. This retrospective, single-center case series included 25 critically ill patients with carbapenem-resistant or multidrug-resistant Gram-negative infections treated with cefiderocol between May 2024 and October 2025 in a mixed ICU of a tertiary hospital in Romania. Microbiological cure was defined as eradication of the designated target pathogen at the end of therapy. Clinical evolution was assessed using the Acute Physiology and Chronic Health Evaluation II (APACHE II) and Sequential Organ Failure Assessment (SOFA) scores, as well as inflammatory biomarkers including white blood cell count (WBC), C-reactive protein (CRP), and procalcitonin (PCT). Klebsiella pneumoniae was the predominant pathogen, identified in 23 of 25 patients (92%), followed by Acinetobacter baumannii (11/25, 44%) and Pseudomonas aeruginosa (6/25, 24%). As multiple pathogens were co-isolated in 16 patients (64%), percentages exceed 100% and are reported as proportions of patients rather than of total isolates. Microbiological cure was achieved in 68% of patients. Mortality was markedly higher in patients without microbiological eradication (88% vs. 35%). Higher baseline APACHE II (HR 1.18, 95% CI 1.02-1.37) and SOFA scores (HR 1.33, 95% CI 1.07-1.65) were associated with increased mortality. Early initiation of cefiderocol (≤10 days from ICU admission) was associated with improved microbiological and clinical outcomes compared to delayed treatment. Reductions in severity scores and inflammatory markers, including C-reactive protein (CRP) and procalcitonin (PCT), were observed during therapy. Pathogen type and combination therapy were not clearly associated with outcomes in this cohort. Cefiderocol was observed in association with clinically relevant rates of microbiological eradication and improvements in clinical parameters in critically ill patients with MDR Gram-negative infections. Outcomes appeared to be primarily determined by baseline disease severity, while earlier initiation of therapy was associated with more favourable microbiological and clinical outcomes, although causality cannot be established given the observational design and absence of a comparator group. These findings are hypothesis-generating and supportive of a potential role for cefiderocol as a salvage option in high-risk ICU populations, pending validation in larger, prospective, controlled studies.
proteins
2026-08-27 | Impact of Lysine-Mediated C-Terminal Dimerization of Anoplin on Killing Kinetics and Antibiotic Interaction Profiles.
Antimicrobial resistance (AMR) limits the efficacy of conventional antibiotics, particularly in infections caused by multidrug-resistant bacteria. anoplin, a short membrane-active antimicrobial peptide, represents a promising scaffold for structural optimization. This study evaluated the antimicrobial performance of anoplin and its C-terminal lysine-mediated dimer, (anoplin)2K, against clinically relevant Gram-positive and Gram-negative bacteria, including carbapenemase-producing and non-producing Klebsiella pneumoniae strains. Minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), time-kill kinetics, checkerboard interaction assays, and hemolytic activity were determined. While MIC values showed moderate differences between the peptides, (anoplin)2K demonstrated enhanced bactericidal kinetics, achieving complete eradication of Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa within 60 min at 256 µM. Additive effects predominated in combination assays, with selective synergism observed for sulfamethoxazole-trimethoprim. Reduced susceptibility was observed for carbapenemase-producing K. pneumoniae. Although the dimeric analogue exhibited increased hemolytic activity at higher concentrations, the results indicate that C-terminal dimerization modulates killing dynamics and enhances antimicrobial performance. These findings support further optimization of anoplin-derived dimers as potential adjunct strategies against multidrug-resistant pathogens.
2026-04-23 | Marine antimicrobial peptide scyreprocin exhibits therapeutic potential against multidrug-resistant bacteria in wound and lung infections with low resistance.
Antibiotic resistance, driven by multidrug-resistant (MDR) pathogens, poses a major global health threat. Antimicrobial peptides (AMPs) have garnered significant attention as promising therapeutic agents for combating MDR bacteria. Here, we demonstrate the potent antimicrobial activity of scyreprocin against MDR strains, including Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Notably, scyreprocin eradicated the tested strains without inducing drug resistance, inhibited biofilm formation, and eliminated persister cells. In terms of in vivo efficacy, scyreprocin displayed excellent activity against S. aureus and K. pneumoniae in a full-thickness wound infection model. Furthermore, administration of scyreprocin reduced bacterial burden in a K. pneumoniae lung infection model, thereby attenuating the pulmonary inflammatory response. Crucially, under cumulative administration of 25 mg/kg for 5 days, scyreprocin treatment via intravenous injection exerted no in vivo toxicity to mice. Mechanistic studies indicated that scyreprocin triggered membrane damage by causing rapid membrane permeability and leakage. Taken together, the marine-sourced scyreprocin demonstrates effective therapeutic potential for treating infections caused by drug-resistant pathogens.
2026-03-25 | Antimicrobial Peptides and ESKAPEE Pathogens: A New Frontier in the Fight Against Antimicrobial Resistance.
Antimicrobial resistance is the most critical global health challenge, largely complicating the treatment of infections caused by multi-drug-resistant pathogens. Among them, ESKAPEE pathogens comprise Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species, and Escherichia coli, which emerged as significant pathogens due to their ability to evade conventional antibiotics. These pathogens cause millions of infections and thousands of deaths every year, mainly in the healthcare sector. Their resistance mechanisms may include modification of targets for antibiotics, increased efflux pump activity, decreased influx, and inactivation of antibiotics. Antimicrobial peptides (AMPs) represent a new candidate whose broad-spectrum activity against microorganisms often protects against susceptible pathogens. AMPs, naturally present in most living organisms as part of innate immunity, are now synthetically produced to harness their antimicrobial properties in therapeutic applications. Moreover, their mechanisms of action make them unique and capable of circumventing the classical resistance pathways. Thus, they offer hope in combating ESKAPEE pathogens. This review discusses the prevalence and clinical significance of ESKAPEE pathogens, their resistance mechanisms, and the possible roles of AMPs in developing effective therapy. With these escalating trends in AMR globally, understanding their dynamics is of prime importance to improve infection control measures and patient outcomes in critical care environments. In addition to an overview of available information on the biology and drug-resistance mechanisms of these pathogens, the review also evaluates the antimicrobial activity of AMPs against multidrug-resistant bacteria, discusses their benefits compared to traditional antibiotics, and highlights significant drawbacks that could limit their clinical use.
2026-02-26 | Pharmacodynamic evaluation of BRII-693, a next-generation synthetic macrocyclic peptide antibiotic, in the neutropenic mouse thigh and lung infection models against gram-negative pathogens.
BRII-693 is a next-generation synthetic macrocyclic peptide antibiotic for infections caused by drug-resistant gram-negative pathogens. This study evaluated the pharmacodynamic activity of BRII-693 against common gram-negative pathogens using neutropenic mouse thigh (11 strains) and lung (15 strains) infection models. BRII-693 exhibited dose-dependent increases in pharmacokinetic exposure in both plasma and epithelial lining fluid (ELF). Due to its prolonged elimination half-life within ELF, the ELF area under the curve (AUC) was higher than plasma AUC on a mg/kg basis. In dose-ranging PK/PD studies, BRII-693 demonstrated dose-dependent antibacterial activity. In both the thigh and lung models, bacterial stasis was achieved at 24 h plasma AUC/MIC values of 1-19 for Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii, and 1-log kill required only modestly higher targets given the steep exposure-response relationships. Higher target exposures were noted for Pseudomonas aeruginosa studies. In the lung model, BRII-693 achieved robust cidal endpoints against all tested organisms. Maximal effect (3-4 log reduction in bacterial burden) converged at a 24 h plasma AUC/MIC value of 50. These findings demonstrate robust PK/PD profile and in vivo efficacy of BRII-693 against clinically relevant gram-negative pathogens, supporting its potential as a next-generation macrocyclic peptide antibiotic.
2026-02-24 | Myeloid-derived interleukin-10 induced by thrombospondin-1 mediates host defense and regulates inflammation during acute bacterial lung infection
ABSTRACT Pseudomonas aeruginosa ( P. aeruginosa ) is a leading cause of hospital- and ventilator-associated pneumonia, driven by virulence factors that damage lung tissue. Neutrophils and monocytes are myeloid immune cells that play key roles in host defense during pulmonary infection against P. aeruginosa ; although if not properly regulated, their inflammatory activity can lead to severe lung injury. Thrombospondin-1 (TSP-1) is a host glycoprotein that regulates neutrophil activation in the lungs during P. aeruginosa infection, protecting the host from mortality. Here, we demonstrate that in addition to regulating the pro-inflammatory phenotype of neutrophils, during P. aeruginosa infection, TSP-1 induces IL-10 in the lung tissue of mice inoculated with this bacterium. Our data show that neutrophils and Ly6C + monocytes are major sources of lung IL-10 during the first 48 h post-infection, a cytokine that is required for host survival, host defense, and to reduce lung inflammation and injury. Further in vitro studies determined that TSP-1 induces IL-10 production in lipopolysaccharide-stimulated CD11b + Ly6G + Ly6C + cells differentiated from bone marrow precursors through a mechanism dependent on the transcription factor peroxisome proliferator-activated receptor gamma (PPARγ). Importantly, intratracheal transfer of IL-10 +/+ CD11b + Ly6G + Ly6C + cells 1 day before infection to Thbs1 −/− mice restored their ability to produce IL-10 in the lungs, improved host defense, and reduced lung inflammation and permeability upon infection. Altogether, our data show that TSP-1 induces IL-10 production in neutrophils and monocytes, enhancing host defense while reducing lung inflammation.
vaccines
2026-09-18 | Live auxotrophic vaccines contribute to protection against chronic lung infections caused by Pseudomonas aeruginosa in C57BL/6 mice.
Pseudomonas aeruginosa causes severe, often multidrug-resistant lung infections, especially in individuals with cystic fibrosis, highlighting vaccination as a promising preventive approach. This study evaluated intranasal and intradermal immunization with a D-glutamate auxotrophic P. aeruginosa strain (PAO1 ΔmurI) and two of its derivatives, one with additional D-alanine auxotrophy and another exhibiting reduced lipopolysaccharide-associated toxicity, in C57BL/6 mice using both acute and chronic lung infection models. Mice received two or three doses at various intervals, and safety was assessed through clinical and weight monitoring. A high-dose, 2-administration intranasal regimen protected against acute infection but induced transient weight loss, while a lower-dose, 3-administration regimen minimized toxicity. Immunized mice exhibited robust IL-17A production and increased IFN-γ responses. Following challenge with mucoid strains, vaccinated mice showed reduced lung bacterial loads, suggesting a partial protection against chronic infection. These findings support the potential of auxotrophic live vaccines to mitigate disease severity in patients with cystic fibrosis.
2026-08-27 | Protective-Antigen Scaffold Nanoparticle Vaccine Overcomes Carrier-Induced Suppression and Immunosenescence to Protect against Pseudomonas aeruginosa Pneumonia
Abstract Multidrug-resistant Pseudomonas aeruginosa (PA) causes severe infections, with severe burden especially in older adults. Vaccines remain effective and are urgently needed despite immunosenescence. Self-assembling nanoparticles can enhance vaccine immunogenicity, but their translational use is constrained by the useless anticarrier immunity and carrier-induced epitope suppression (CIES). Herein, we developed a protective-antigen-based nanoparticle platform in which the PA chaperonin GroEL, an intrinsically self-assembling protective antigen, serves as the scaffold for a fusion immunogen reGroEL-PO, which displays the PcrV-OprI antigen (rePO). In mice, pre-existing anti-GroEL immunity did not blunt responses but enhanced anti-rePO immunity. Mechanistically, reGroEL-PO increased antigen uptake by antigen-presenting cells, promoted dendritic-cell maturation and accelerated both humoral and cellular immunity. In addition, reGroEL-PO elicited immune responses and conferred protection in adult and aged mice. These data demonstrate reGroEL-PO as a PA vaccine candidate and illustrate a nanoparticle design that leverages protective carriers and circumvents CIES effects.
2025-07-25 | Development of a bivalent protein subunit vaccine against infection by Pseudomonas aeruginosa and Staphylococcus aureus
Pseudomonas aeruginosa (PA) and Staphylococcus aureus (SA) are members of the ESKAPE pathogens, a group of bacteria that are a threat to human health due to their ability to resist antibiotics. They are known to cause severe infections, often as co-morbidities, in individuals with conditions such as people with cystic fibrosis, diabetes, wounds, pneumonia, and critically ill patients requiring intubation leading to ventilator-associated pneumonia. Emergence of multi-drug resistance in SA and PA is making traditional antibiotic treatment ineffective and unfortunately there are no licensed vaccines to prevent MRSA or PA infections. We have demonstrated that when delivered intranasally (IN) L-PaF, a genetic fusion of the PA type III secretion system (T3SS) proteins PcrV and PopB (PaF) with LTA1, the active moiety of heat-labile enterotoxin from enterotoxigenic E. coli, protects against PA. L-PaF was formulated as a nanoemulsion (ME) to increase the protective immune response against clinically relevant PA strains in a mouse lung colonization model. With the addition NEAT2, the heme capturing domain of the SA protein IsdB, a bivalent vaccine was generated. IN administration of the bivalent formulation protected MRSA pre-exposed mice from both MRSA and PA infection. Sera from mice vaccinated with our formulation contained strong IgG titers with high levels of opsonophagocytic killing of homologous and heterologous PA and SA strains. Additionally, the bivalent L-PaF/NEAT2 formulation elicited stimulation of IL-17A and IL-2 cytokines. Because established PA and SA lung infection models with rabbits better reproduce the clinical hallmarks of severe human acute pneumonia, rabbits were immunized with the bivalent L-PaF/NEAT2 formulation. All of the vaccinated rabbits survived the challenges while the controls did not. These findings demonstrate that our L-PaF/ME/NEAT2 formulation has potential as a broad-spectrum vaccine against both SA and PA infection.
2025-07-06 | In silico development of a broad-spectrum vaccine against ESKAPE pathogens.
Antimicrobial-resistant ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter cloacae) have significantly restricted therapeutic alternatives for critical infections, consequently contributing to increase the severity and mortality of infectious illnesses that represent a significant global health challenge. Vaccination as a preventive measure can be crucial in substantially reducing bacterial infections and is potentially effective against antibiotic-resistant bacteria. This study shows the design of an epitope-based vaccine capable of neutralizing shared antigenic determinants present among the ESKAPE pathogens. The pangenome of the ESKAPE pathogens was analyzed to extract the core proteome. This approach facilitated reverse vaccinology analysis to identify antigenic proteins within this bacterial group. The study revealed similar structures in porins OmpA, OprD, and TolC, as well as the collagen-binding adhesins Acm and Cna. These proteins were then utilized to predict T-cell and B-cell epitopes, selecting those with their best physicochemical properties, antigenicity, non-allergenicity, and lack of toxicity. Additionally, epitopes located on the surface of the antigens and capable of coupling with HLA molecules were prioritized. In this computational approach, we engineered a construct incorporating the adjuvant RS09, a TLR4 agonist, and immunogenic epitopes connected by linkers. We assessed the stability of their interaction with pattern recognition receptors of the immune system through molecular docking and molecular dynamics simulations. The in silico immune simulation demonstrated that the vaccine could trigger humoral and cell-mediated immune responses. The resulting construct potentially represents an effective and safe vaccine candidate to prevent infections caused by the ESKAPE group.
2024-12-25 | Hybrid Cell Membrane-Engineered Nanocarrier for Triple-Action Strategy to Address Pseudomonas aeruginosa Infection.
Bacterial infections resistant to antimicrobial treatments, particularly those caused by Pseudomonas aeruginosa (P. aeruginosa), frequently lead to elevated mortality rates. Tackling this resistance using therapeutic combinations with varied mechanisms has shown considerable promise. In this study, a bioinspired nanocarrier is successfully designed and engineered for targeted antibiotic delivery and toxin/bacteria clearance. This is achieved by encapsulating antibiotic-loaded framework nucleic acids with hybrid cell membranes acquired from neutrophils and platelets. By coating the hybrid membrane outside the shell, nanocarriers are endowed with the function of neutrophil-like chemotaxis and platelet-like bacteria adhesion to achieve the first stage of inflammation targeting. Based on the specific binding of bacteria toxin to the hybrid membrane, the release of antibiotic-loaded framework nucleic acids is triggered by toxin-mediated membrane lysis to fulfill the second stage of toxin neutralization and bacteria killing. Meanwhile, the immunomodulation potential of framework nucleic acids enables nanocarriers to accomplish the third stage of reversing the immunosuppressive microenvironment. In mouse models of acute and chronic P. aeruginosa pneumonia, the nanocarriers can reduce bacterial burden at a low dosage and decrease mortality with negligible toxicity. In sum, these findings have illustrated the remarkable capability of nanocarriers in treating recalcitrant bacterial infections.
gene therapies
2026-09-30 | A broad-host-range inhalable phage cocktail for treatment of multidrug-resistant Pseudomonas aeruginosa pulmonary infections.
The growing threat of multidrug-resistant (MDR) Pseudomonas aeruginosa (P. aeruginosa) has created an urgent need for novel therapeutic strategies to combat refractory lung infections. The limited efficacy of traditional antibiotics against this pathogen highlights the necessity of developing alternative treatments. Our study aims to develop a broad-spectrum bacteriophage cocktail suitable for nebulization and to evaluate its antibacterial efficacy and safety in respiratory infections caused by MDR P. aeruginosa. We constructed a seven-phage cocktail by selecting phages with complementary host ranges, strong lytic activity, and different receptor targets. The antimicrobial and anti-biofilm activity of the cocktail was assessed in vitro against clinical MDR P. aeruginosa isolates. The therapeutic efficacy and safety were further investigated in a murine pneumonia model following nebulized administration. The phage cocktail demonstrated lytic activity against nearly 90% of 152 clinical P. aeruginosa isolates, indicating broad coverage. Compared to single phages or antibiotics, the cocktail showed superior activity in both inhibiting and disrupting biofilms. In the murine pneumonia model, nebulized phage therapy improved survival, reduced bacterial burdens in lung and liver, and alleviated infection-related histopathological damage. Safety assessment revealed no obvious hematological, biochemical or histopathological abnormalities in both acute and long-term administration. High-dose nebulized administration of this phage cocktail reduced bacterial burden and showed favorable tolerability in a murine model of MDR P. aeruginosa pneumonia. These findings provide preclinical evidence supporting further evaluation of inhaled phage cocktails as a potential therapeutic strategy for refractory respiratory infections.
2026-06-27 | Inhalable bacteriophage endolysins: a novel therapeutic strategy for drug-resistant bacterial pulmonary infections - a comprehensive review.
Pulmonary infections caused by multidrug-resistant (MDR) bacteria pose a severe global health threat with high mortality rates, especially in hospital-acquired pneumonia. The stagnation of new antibiotic development underscores the urgent need for alternative therapeutics. This review summarizes recent advances in the application of bacteriophage endolysins against major MDR respiratory pathogens, including Staphylococcus aureus, Streptococcus pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae. We focus on their mechanisms of action, synergistic effects with antibiotics, and efficacy against biofilms. Endolysins demonstrate potent and species-specific lytic activity against a broad spectrum of MDR bacteria. A key advantage is their low propensity for inducing resistance. Critically, when administered via optimized inhalation delivery systems, endolysins can achieve high local concentrations in the lungs - though this depends on factors such as the aerosol device, formulation properties and patient-related variables - effectively eradicating pathogens in animal models of pneumonia with minimal systemic toxicity. This direct pulmonary delivery approach bypasses many challenges associated with systemic administration and enhances therapeutic outcomes. Endolysins represent a promising paradigm shift in combating drug-resistant bacterial pulmonary infections. Their rapid lytic activity, synergy with conventional antibiotics, and suitability for inhalable formulation position them as a potent adjunct or alternative therapy. While challenges in stabilization and large-scale production remain, advancing inhalation delivery systems for endolysins holds immense potential to holds immense potential to revolutionize the treatment of recalcitrant respiratory infections.
2026-03-27 | Mapping the clinical use of inhaled bacteriophages in respiratory infections caused by multidrug-resistant pathogens: a scoping review.
Inhaled bacteriophage therapy is an emerging adjunctive strategy for treating lower respiratory tract infections caused by multidrug-resistant (MDR) pathogens. However, the clinical evidence base remains fragmented. We conducted a scoping review to map the current landscape of human studies using nebulized, aerosolized, or dry-powder phage therapy for pulmonary infections. We systematically searched PubMed, Scopus, Web of Science, and ClinicalTrials.gov for clinical studies published up to 1 June 2025. Eligible studies included clinical trials, cohort studies, and case reports/series reporting at least one dose of inhaled lytic phage for bacterial respiratory infections. Screening followed PRISMA-ScR guidelines. Key data were extracted on patient characteristics, pathogens, phage preparations, delivery methods, safety, and outcomes. Of 507 records identified, 31 studies met inclusion criteria: six clinical trials and 25 case reports or series. Target infections included ventilator-associated pneumonia, cystic fibrosis exacerbations, and chronic bronchiectasis, primarily due to Pseudomonas aeruginosa, Acinetobacter baumannii, or Klebsiella pneumoniae. Delivery methods varied widely, including nebulizers, dry-powder inhalers, and endotracheal instillation. Most studies reported clinical or microbiological improvement without major adverse events, though few used standardized outcome measures. Inhaled phage therapy has shown promise in compassionate and investigational settings for MDR respiratory infections. Despite heterogeneity in delivery methods and outcome reporting, preliminary data suggests feasibility and safety. Standardized protocols and controlled trials are needed to define its role in pulmonary antimicrobial therapy.
2026-02-22 | <b>Evaluating a Novel Bacteriophage Cocktail for Eradicating Pseudomonas aeruginosa Biofilms in Ventilator-Associated Pneumonia</b>
Background: Ventilator-associated pneumonia caused by Pseudomonas aeruginosa remains difficult to treat because of multidrug resistance and biofilm formation, which reduce antibiotic penetration and contribute to persistent infection in mechanically ventilated patients. Objective: To evaluate the efficacy of adjunctive nebulized bacteriophage cocktail therapy in reducing P. aeruginosa biofilm burden and improving microbiological and clinical outcomes in ventilator-associated pneumonia. Methods: A parallel-group randomized controlled trial was conducted in tertiary care intensive care units over five months. Seventy-two mechanically ventilated adults with microbiologically confirmed P. aeruginosa ventilator-associated pneumonia and evidence of biofilm formation were randomized to receive either standard culture-guided antibiotic therapy plus nebulized bacteriophage cocktail twice daily for 14 days or standard care alone. Primary outcomes were biofilm biomass reduction and microbiological clearance; secondary outcomes included duration of mechanical ventilation, Clinical Pulmonary Infection Score, and intensive care unit stay. Results: The final analyzed cohort included 63 participants. Day-14 biofilm biomass was significantly lower in the intervention group than in controls (0.62 ± 0.18 vs 0.94 ± 0.22 OD units; p<0.001). Culture negativity was higher with bacteriophage therapy (75.0% vs 45.2%; p=0.01). The intervention group also had shorter mechanical ventilation duration, lower day-14 Clinical Pulmonary Infection Score, and reduced intensive care unit stay (p<0.05 for all). Conclusion: Adjunctive nebulized bacteriophage cocktail therapy improved biofilm reduction, microbiological clearance, and short-term clinical outcomes in P. aeruginosa ventilator-associated pneumonia.
2025-12-16 | Navigating the Crisis of Multidrug-Resistant Infections in Infants to Teenagers: Regional Variability and Global Solutions
Superbacteria, or multidrug-resistant (MDR) microorganisms, pose a major global health threat, particularly in regions such as South Asia and sub-Saharan Africa. Bacteria, such as Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa, are resistant to multiple antibiotics, making infections more difficult to treat. These resistant infections cause millions of deaths annually, with vulnerable groups, such as neonates and children, being particularly at risk. The overuse of antibiotics in medicine and livestock, along with weak healthcare systems, accelerates the spread of antibiotic resistance, especially in countries such as India, China, and Pakistan. Common resistant infections include urinary tract infections, neonatal sepsis, and ventilator-associated pneumonia (VAP). Resistance to antibiotics, such as carbapenems and third-generation cephalosporins, along with the rise of ESBL-producing bacteria, complicates treatment, particularly in neonatal intensive care units (NICUs). This paper reviews global data on superbacteria, focusing on neonatal and pediatric populations, highlighting the need for better diagnostics, novel treatments (e.g., phage therapy), antimicrobial stewardship, infection control, and global cooperation to combat the growing threat of resistance.
other
2026-09-23 | The interface of biofilm and immune system for Gram-negative ESKAPE pathogens.
The ESKAPE group of pathogens comprises Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp., which are capable of developing profound biofilms while infecting host tissues and medical devices. In addition to acting as a barrier to antimicrobial treatments and as a niche for the transmission of antibiotic resistance genes, biofilm-associated extracellular polymeric substances and metabolites modulate innate and adaptive immune responses. With the rise of emerging resistance against last-resort antibiotics, divulging the cross-talk between ESKAPE biofilms and the host immune system is essential for designing therapies aimed at immunoactivation. Compared with their Gram-positive ESKAPE counterparts, limited therapeutics coupled with higher mortality-associated phenotypes make Gram-negative ESKAPE pathogens an urgent priority for immediate action. The ultimate goals for strategizing such interventions are to disrupt biofilm integrity, restore immune efficacy, and improve clinical outcomes against multi- or pan-drug-resistant pathogens. Against this backdrop, this review highlights the alteration of the host immune system and the modifications in innate and adaptive immune responses caused by Gram-negative ESKAPE pathogens. In addition, the possibility of success of immunomodulation-based strategies in combating bacterial biofilms and accentuating the activity of known antimicrobials is discussed objectively.
2026-08-28 | Broad-Spectrum Protective Efficacy of a Fully Human Antibody Cocktail Targeting PcrV, ETA, and PA0833 Against Pseudomonas aeruginosa Infection.
Pseudomonas aeruginosa (P. aeruginosa) pose a global health threat, with carbapenem-resistant strains in particular posing a grave threat due to high mortality rates and limited treatment options for antibiotic-refractory infections. To address the inherent limitations of single-target therapies, this study developed a multi-target fully human monoclonal antibody (mAb) cocktail targeting three core virulence factors: a key component of the type III secretion system, exotoxin A, and an outer membrane protein. Using a fully human transgenic mouse platform, we generated and characterized three high-affinity mAbs targeting PcrV (U0151, Kd = 2.69 nM), ETA (U0462, Kd = 1.75 nM), and PA0833 (U0057, Kd = 0.34 nM). Functional assays confirmed robust target-specific activities, including neutralization of PcrV-mediated hemolysis, inhibition of ETA-induced cytotoxicity, and enhancement of cell-mediated bacterial clearance. In mouse models of systemic infection and acute pneumonia caused by PAO1, a significant enhancement in efficacy was observed when three types of antibodies were used in combination, increasing protective rates to 78% and 88%, respectively, whereas monotherapies achieved protective rates of no more than 38%. Combined treatment also reduced bacterial burden, alleviated tissue damage, and suppressed excessive neutrophil infiltration. Furthermore, it showed immune protection against several clinical isolates of P. aeruginosa, including carbapenem-resistant strains, within these limits, the data support the three-antibody combination as a candidate adjunctive immunotherapy for multidrug-resistant P. aeruginosa infection.
2026-06-17 | Engineering low-endotoxin lipid A in a double auxotroph Pseudomonas aeruginosa to develop safer whole-cell vaccines.
Pseudomonas aeruginosa is a highly adaptable Gram-negative bacterium causing severe respiratory infections, particularly in vulnerable populations. The rise of antimicrobial resistance highlights the urgent need for effective vaccines. We previously developed a live-attenuated vaccine candidate, PAO1 ΔmurI Δalr ΔdadX, a genetically stable double auxotrophic strain that exhibited dose-dependent reactogenicity upon intranasal administration in mice, likely due to lipid A component of lipopolysaccharide (LPS). To reduce LPS-associated toxicity while preserving immunogenicity, we engineered novel strains by inactivating genes involved in lipid A biosynthesis (htrB1, htrB2) or modification (pagP, pagL). Lipid A structural modifications were confirmed by MALDI-TOF MS. Mutants were evaluated for Toll-like receptor 4 (TLR4) activation, virulence attenuation, and their ability to induce immune responses and protection in an acute pneumonia model. All engineered strains displayed modified lipid A structures. Mutations in htrB1 and htrB2 reduced TLR4 activation and significantly attenuated virulence following intraperitoneal challenge in mice. Inactivation of pagL resulted in minimal attenuation, whereas pagP inactivation led to marked attenuation without altering TLR4 activation. In the acute pneumonia model, all mutants elicited robust systemic and mucosal immune responses, and conferred strong protection, despite transient weight loss following intranasal administration. Targeted lipid A modification represents an effective strategy to reduce in vitro reactogenicity while preserving immunogenicity in live-attenuated P. aeruginosa vaccine candidates. Although further optimization may minimize residual in vivo effects, these findings support the potential of engineered strains as vaccine candidates for preventing respiratory infections caused by P. aeruginosa.
2026-06-17 | Engineered antibodies bypass bacterial immune evasion to drive complement-mediated protection against lethal infections.
The expanding global crisis of bacterial infections caused by antimicrobial-resistant pathogens has resulted in an urgent need for therapeutics. Previous efforts to target pathogen surface antigens with monoclonal antibodies (mAbs) have sought to activate the complement system, primarily through the antibody-dependent classical pathway. However, most mAbs have induced insufficient complement activation because pathogen evasion strategies disrupt the complex spatiotemporal requirements for activation of the classical pathway initiation complex C1. To address this, we developed a targeted complement activation therapy (T-CAT), which uses antibodies furnished with the enzymatic capability to initiate complement activation directly on the bacterial surface without involvement of the classical pathway initiation complex. We found that T-CAT mAbs directed against bacterial surface antigens can overcome the strategies that pathogens evolved to escape from classical pathway-mediated clearance by the immune system. We further demonstrated that T-CAT mAbs could safely and effectively be used to treat infectious disease in experimental murine models of sepsis and pneumonia caused by Klebsiella pneumoniae, Pseudomonas aeruginosa, Streptococcus pneumoniae, and Neisseria meningitidis. Together, these data highlight the potential for T-CAT as a next-generation mAb platform with broad applicability against diverse microbial species, including multidrug-resistant pathogens, without promoting drug resistance.
2026-06-12 | AZinc-Coordinated Glycopolymer for Inhibiting BacterialToxins in Management of Acute Pneumonia
Bacterial toxins play a critical role in infections by compromising host defenses, causing host cell death, and inducing excessive immune activation, ultimately leading to severe tissue damage and increased mortality. To combat both the pathogen and its associated toxins, this study developed a bacteria-targeting zinc-coordinated glycopolymer designed to deliver antisense oligonucleotides (ASOs) and absorb lipopolysaccharides (LPS). The functional polymer enhances Pseudomonas aeruginosa internalization efficiency through galactose-mediated bacterial surface interaction. By delivering multiple ASOs, the nanoparticle enables the dual suppression of bacterial growth and quorum sensing, exhibiting potent antibacterial activity. Furthermore, zinc ions coordinated within the glycopolymer impart the ability to bind and adsorb LPS, thereby mitigating the toxin-induced damage to host cells. In a murine model of acute pneumonia, this approach significantly improved survival rates and reduced pro-inflammatory cytokine levels. Consequently, pulmonary inflammation was suppressed, bacterial toxin-induced damage was alleviated, and tissue integrity was preserved. This synergistic strategy of combined sterilization and toxin neutralization offers a novel and synergistic therapeutic approach to combating bacterial infections.
small molecules
2026-09-30 | Qiguiyin Formula Combined with Fosfomycin Alleviates Lung Injury Induced by Pseudomonas Aeruginosa Infection via the Gut-Lung Axis.
Multidrug-resistant Pseudomonas aeruginosa (MDR-PA) pneumonia is characterized by limited clinical antimicrobial options, severe inflammatory damage and high mortality. MDR-PA infection can trigger intestinal microecological imbalance and immune disorders. Qiguiyin Formula is a classic traditional Chinese medicinal compound clinically applied for infections caused by drug-resistant Pseudomonas aeruginosa. This study aimed to clarify the relationship between intestinal flora dysbiosis induced by MDR-PA infection and pathological injuries in the lung and intestine, as well as evaluate the therapeutic potential of Qiguiyin Formula combined with fosfomycin, and further elaborate its mechanism of action from the perspective of the gut-lung axis. Mouse models of multidrug-resistant Pseudomonas aeruginosa (MDR-PA) infection and corresponding intervention models treated with Qiguiyin Formula and fosfomycin were established. HE staining, RT-qPCR, chemiluminescence immunoassay, 16S rRNA sequencing and non-targeted metabolomics analysis were applied to assess immune damage and gut microbiota structure in lung and intestinal tissues. MDR-PA infection leads to severe imbalance of the intestinal flora, manifested by an increase in pathogenic bacteria (Escherichia coli, Shigella) and a significant decrease in beneficial bacteria (Lactobacillus, Bifidobacterium), and an increase in inflammatory metabolites such as arachidonic acid, linoleic acid, and α-linolenic acid, causing disorders in lipid metabolism pathways and MAPK signaling pathways. The HE staining results show that MDR-PA infection damages the lung structure, triggers alveolar inflammation, downregulates the expression of ZO-1, damages the colonic barrier, and induces a pro-inflammatory cytokine storm, resulting in a high mortality rate. In terms of treatment, the intervention of the Qiguiyin Formula combined with fosfomycin demonstrates the advantages of a synergistic effect: improving the imbalance of intestinal flora, reshaping core metabolic pathways such as lipids, amino acids, and arginine, repairing the integrity of the intestinal barrier, and inhibiting the expression of inflammatory factors. MDR-PA infection disrupts intestinal flora homeostasis and induces metabolic disorders. The combined use of Qiguiyin Formula and fosfomycin alleviates pulmonary injury by improves the diversity and stability of the intestinal microbiota, corrects the abnormal activation of lipid and amino acid metabolic pathways, and restores the normal metabolic signals of the microbiota, thereby inhibiting lung damage.
2026-09-15 | A Four-Center Study on the Activity of Aztreonam and Aztreonam-Avibactam Combination Against Clinical Isolates of Gram-Negative Bacilli Producing Representatives of Ambler Class A, B, C or D β-Lactamases.
We aimed to investigate the activity of aztreonam and aztreonam-avibactam combination against gram-negative bacilli producing different types of β-lactamases. Activity of aztreonam and aztreonam-avibactam against 166 isolates (33 AmpC-producing, 33 ESBL-producing, 66 carbapenemase-producing Enterobacterales, 34 metallo-β-lactamase-producing P. aeruginosa) from four centers in Türkiye was determined using gradient diffusion method. Aztreonam susceptibility rates among AmpC-producing, ESBL-producing and carbapenemase-producing Enterobacterales were 75.8%, 3% and 6.1%, respectively. All AmpC-producing or ESBL-producing Enterobacterales were susceptible to aztreonam-avibactam. ESBL-producing K. pneumoniae had significantly higher aztreonam-avibactam MICs compared with ESBL-producing E. coli. K. pneumoniae carrying blaCTX-M + blaSHV + blaTEM had significantly higher aztreonam-avibactam MICs when compared to those carrying only blaCTX-M. Aztreonam-avibactam susceptibility rate among carbapenemase-producing K. pneumoniae (100%) was significantly higher than that observed for carbapenemase-producing E. coli (65%). Metallo-β-lactamase-producing P. aeruginosa had significantly higher aztreonam-avibactam MICs (MIC50/90: 16/96 mg/L) when compared to metallo-β-lactamase-producing Enterobacterales (MIC50/90: 0.19/8 mg/L). Aztreonam-avibactam may be an option for treatment of infections caused by ESBL-producing or AmpC-producing K. pneumoniae, E. coli and carbapenemase-producing K. pneumoniae. However, aztreonam-avibactam resistance may be encountered in a considerable portion of carbapenem-resistant E. coli isolates. High aztreonam-avibactam MIC values suggest limited in vitro activity of aztreonam-avibactam against MBL-producing P. aeruginosa isolates in this collection.
2026-09-09 | Sorafenib analogues exhibit dual Colistin-potentiating and anti-MRSA activity.
In response to the antimicrobial resistance (AMR) global health crisis, physicians have been forced to employ antibiotics of last resort such as colistin, which had previously been removed from clinics due to toxicity concerns. The increase in colistin usage has in turn resulted in the increased incidence of colistin-resistant isolates, making novel therapeutic options for infections caused by these pathogens a priority. We previously reported that sorafenib, a eukaryotic kinase inhibitor, is a colistin adjuvant, augmenting colistin activity against colistin-resistant Klebsiella pneumoniae and Acinetobacter baumannii. Herein, we describe the generation of a library of analogues based upon the sorafenib scaffold, lead compounds from which sensitize colistin-resistant K. pneumoniae, A. baumannii, and Pseudomonas aeruginosa to colistin, and exhibit reduced cytotoxicity compared to sorafenib. We also describe the standalone antimicrobial activity of these sorafenib analogues against methicillin-resistant Staphylococcus aureus (MRSA). Lead compound NDM-773 lowers the colistin minimum inhibitory concentration (MIC) against K. pneumoniae B9 from 512 μg mL-1 to 2 μg mL-1 at 1.5 μM, against A. baumannii 4106 from 1024 μg mL-1 to 1 μg mL-1 at 4 μM, and against P. aeruginosa TRPA162 from 8192 μg mL-1 to ≤0.125 μg mL-1 at 7.5 μM. NDM-773 acts as a standalone antibiotic against MRSA with an MIC of 0.781 μM (0.398 μg mL-1) and a frequency of mutation rate of <10-11 against MRSA BAA-1556. NDM-773 exhibits over three-fold reduction in HepG2 toxicity compared to sorafenib, and has therapeutic indices (TIs) up to 35.6 as a colistin adjuvant, and 68.4 as an MRSA antibiotic.
2026-08-27 | SEVERE AND RECURRENT PSEUDOMONAS AERUGINOSA INFECTIONS IN CRITICALLY ILL PATIENTS: A CASE SERIES OF PNEUMONIA, SEPSIS, SEPTIC PULMONARY EMBOLI, AND DIABETIC KETOACIDOSIS
Background: Pseudomonas aeruginosa is an important opportunistic pathogen associated with severe healthcare-associatedinfections, particularly among critically ill patients. It can cause pneumonia, bloodstream infection, sepsis, abscesses, and othermetastatic complications. Treatment can be challenging because of its intrinsic and acquired antimicrobial resistancemechanisms. The clinical course may be further complicated by diabetes mellitus, diabetic ketoacidosis (DKA), acuterespiratory distress syndrome (ARDS), prolonged mechanical ventilation, and recurrent infection. Case presentations: Wedescribe three critically ill male patients with severe P. aeruginosa-associated infections requiring intensive care management.Case 1 was a 36-year-old man with newly diagnosed diabetes mellitus and DKA who developed severe P. aeruginosapneumonia complicated by ARDS, septic shock, acute kidney injury, and prolonged mechanical ventilation. Blood andendotracheal aspirate cultures repeatedly yielded P. aeruginosa, reported as susceptible to meropenem and resistant to colistinand polymyxin-B. After initial recovery and discharge, he was readmitted with fever and a left foot abscess. CT pulmonaryangiography demonstrated multiple pulmonary nodules and cavitary lesions suggestive of septic pulmonary emboli. Bloodand pus cultures again yielded P. aeruginosa. Source control was achieved by incision and drainage, and antimicrobial therapywas escalated to ceftazidime-avibactam.Case 2 was a 27-year-old man who presented with high-grade fever, right knee pain, jaundice, severe hypoxemia, andrespiratory failure. He required intubation, mechanical ventilation, prone positioning, and intensive care treatment. Bloodculture initially demonstrated Gram-negative bacilli subsequently identified as P. aeruginosa. He improved followingtreatment but was readmitted with recurrent fever, severe tachycardia, dyspnea, and persistent right knee symptoms. Theavailable records suggest possible musculoskeletal involvement; however, definitive microbiological confirmation fromsynovial fluid or other joint specimens was not available in the source material. Case 3 was a 25-year-old man with diabetesmellitus who presented with severe hyperglycemia, positive urine ketones, high-grade fever, profound hypoxemia, and clinicalfeatures of severe infection. He required emergency intubation, mechanical ventilation, intravenous insulin, fluid resuscitation,and broad-spectrum antimicrobial therapy. Blood and endotracheal cultures subsequently demonstrated P. aeruginosa, reportedas susceptible to meropenem and resistant to colistin. Following culture-directed antimicrobial therapy and metaboliccorrection, he improved and was successfully extubated. Conclusion: These cases demonstrate the heterogeneous andpotentially severe manifestations of P. aeruginosa infection in critically ill patients. Recurrent bacteremia should promptcareful reassessment for persistent or metastatic sources of infection and consideration of definitive source control. Severeinfection may coexist with or precipitate DKA and ARDS, requiring coordinated antimicrobial, metabolic, respiratory, andcritical-care management. Repeated microbiological assessment and antimicrobial susceptibility testing are essential forguiding therapy.
2026-08-27 | Real-World Use of Cefiderocol for Multidrug-Resistant Gram-Negative Infections in Critically Ill ICU Patients: A Single-Center Case Series.
Carbapenem-resistant Gram-negative (CR-GN) infections are associated with high mortality in intensive care units (ICUs), with limited therapeutic options. We aimed to evaluate microbiological and clinical outcomes associated with cefiderocol in critically ill patients with multidrug-resistant (MDR) Gram-negative infections. This retrospective, single-center case series included 25 critically ill patients with carbapenem-resistant or multidrug-resistant Gram-negative infections treated with cefiderocol between May 2024 and October 2025 in a mixed ICU of a tertiary hospital in Romania. Microbiological cure was defined as eradication of the designated target pathogen at the end of therapy. Clinical evolution was assessed using the Acute Physiology and Chronic Health Evaluation II (APACHE II) and Sequential Organ Failure Assessment (SOFA) scores, as well as inflammatory biomarkers including white blood cell count (WBC), C-reactive protein (CRP), and procalcitonin (PCT). Klebsiella pneumoniae was the predominant pathogen, identified in 23 of 25 patients (92%), followed by Acinetobacter baumannii (11/25, 44%) and Pseudomonas aeruginosa (6/25, 24%). As multiple pathogens were co-isolated in 16 patients (64%), percentages exceed 100% and are reported as proportions of patients rather than of total isolates. Microbiological cure was achieved in 68% of patients. Mortality was markedly higher in patients without microbiological eradication (88% vs. 35%). Higher baseline APACHE II (HR 1.18, 95% CI 1.02-1.37) and SOFA scores (HR 1.33, 95% CI 1.07-1.65) were associated with increased mortality. Early initiation of cefiderocol (≤10 days from ICU admission) was associated with improved microbiological and clinical outcomes compared to delayed treatment. Reductions in severity scores and inflammatory markers, including C-reactive protein (CRP) and procalcitonin (PCT), were observed during therapy. Pathogen type and combination therapy were not clearly associated with outcomes in this cohort. Cefiderocol was observed in association with clinically relevant rates of microbiological eradication and improvements in clinical parameters in critically ill patients with MDR Gram-negative infections. Outcomes appeared to be primarily determined by baseline disease severity, while earlier initiation of therapy was associated with more favourable microbiological and clinical outcomes, although causality cannot be established given the observational design and absence of a comparator group. These findings are hypothesis-generating and supportive of a potential role for cefiderocol as a salvage option in high-risk ICU populations, pending validation in larger, prospective, controlled studies.
proteins
2026-08-27 | Impact of Lysine-Mediated C-Terminal Dimerization of Anoplin on Killing Kinetics and Antibiotic Interaction Profiles.
Antimicrobial resistance (AMR) limits the efficacy of conventional antibiotics, particularly in infections caused by multidrug-resistant bacteria. anoplin, a short membrane-active antimicrobial peptide, represents a promising scaffold for structural optimization. This study evaluated the antimicrobial performance of anoplin and its C-terminal lysine-mediated dimer, (anoplin)2K, against clinically relevant Gram-positive and Gram-negative bacteria, including carbapenemase-producing and non-producing Klebsiella pneumoniae strains. Minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), time-kill kinetics, checkerboard interaction assays, and hemolytic activity were determined. While MIC values showed moderate differences between the peptides, (anoplin)2K demonstrated enhanced bactericidal kinetics, achieving complete eradication of Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa within 60 min at 256 µM. Additive effects predominated in combination assays, with selective synergism observed for sulfamethoxazole-trimethoprim. Reduced susceptibility was observed for carbapenemase-producing K. pneumoniae. Although the dimeric analogue exhibited increased hemolytic activity at higher concentrations, the results indicate that C-terminal dimerization modulates killing dynamics and enhances antimicrobial performance. These findings support further optimization of anoplin-derived dimers as potential adjunct strategies against multidrug-resistant pathogens.
2026-04-23 | Marine antimicrobial peptide scyreprocin exhibits therapeutic potential against multidrug-resistant bacteria in wound and lung infections with low resistance.
Antibiotic resistance, driven by multidrug-resistant (MDR) pathogens, poses a major global health threat. Antimicrobial peptides (AMPs) have garnered significant attention as promising therapeutic agents for combating MDR bacteria. Here, we demonstrate the potent antimicrobial activity of scyreprocin against MDR strains, including Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Notably, scyreprocin eradicated the tested strains without inducing drug resistance, inhibited biofilm formation, and eliminated persister cells. In terms of in vivo efficacy, scyreprocin displayed excellent activity against S. aureus and K. pneumoniae in a full-thickness wound infection model. Furthermore, administration of scyreprocin reduced bacterial burden in a K. pneumoniae lung infection model, thereby attenuating the pulmonary inflammatory response. Crucially, under cumulative administration of 25 mg/kg for 5 days, scyreprocin treatment via intravenous injection exerted no in vivo toxicity to mice. Mechanistic studies indicated that scyreprocin triggered membrane damage by causing rapid membrane permeability and leakage. Taken together, the marine-sourced scyreprocin demonstrates effective therapeutic potential for treating infections caused by drug-resistant pathogens.
2026-03-25 | Antimicrobial Peptides and ESKAPEE Pathogens: A New Frontier in the Fight Against Antimicrobial Resistance.
Antimicrobial resistance is the most critical global health challenge, largely complicating the treatment of infections caused by multi-drug-resistant pathogens. Among them, ESKAPEE pathogens comprise Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species, and Escherichia coli, which emerged as significant pathogens due to their ability to evade conventional antibiotics. These pathogens cause millions of infections and thousands of deaths every year, mainly in the healthcare sector. Their resistance mechanisms may include modification of targets for antibiotics, increased efflux pump activity, decreased influx, and inactivation of antibiotics. Antimicrobial peptides (AMPs) represent a new candidate whose broad-spectrum activity against microorganisms often protects against susceptible pathogens. AMPs, naturally present in most living organisms as part of innate immunity, are now synthetically produced to harness their antimicrobial properties in therapeutic applications. Moreover, their mechanisms of action make them unique and capable of circumventing the classical resistance pathways. Thus, they offer hope in combating ESKAPEE pathogens. This review discusses the prevalence and clinical significance of ESKAPEE pathogens, their resistance mechanisms, and the possible roles of AMPs in developing effective therapy. With these escalating trends in AMR globally, understanding their dynamics is of prime importance to improve infection control measures and patient outcomes in critical care environments. In addition to an overview of available information on the biology and drug-resistance mechanisms of these pathogens, the review also evaluates the antimicrobial activity of AMPs against multidrug-resistant bacteria, discusses their benefits compared to traditional antibiotics, and highlights significant drawbacks that could limit their clinical use.
2026-02-26 | Pharmacodynamic evaluation of BRII-693, a next-generation synthetic macrocyclic peptide antibiotic, in the neutropenic mouse thigh and lung infection models against gram-negative pathogens.
BRII-693 is a next-generation synthetic macrocyclic peptide antibiotic for infections caused by drug-resistant gram-negative pathogens. This study evaluated the pharmacodynamic activity of BRII-693 against common gram-negative pathogens using neutropenic mouse thigh (11 strains) and lung (15 strains) infection models. BRII-693 exhibited dose-dependent increases in pharmacokinetic exposure in both plasma and epithelial lining fluid (ELF). Due to its prolonged elimination half-life within ELF, the ELF area under the curve (AUC) was higher than plasma AUC on a mg/kg basis. In dose-ranging PK/PD studies, BRII-693 demonstrated dose-dependent antibacterial activity. In both the thigh and lung models, bacterial stasis was achieved at 24 h plasma AUC/MIC values of 1-19 for Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii, and 1-log kill required only modestly higher targets given the steep exposure-response relationships. Higher target exposures were noted for Pseudomonas aeruginosa studies. In the lung model, BRII-693 achieved robust cidal endpoints against all tested organisms. Maximal effect (3-4 log reduction in bacterial burden) converged at a 24 h plasma AUC/MIC value of 50. These findings demonstrate robust PK/PD profile and in vivo efficacy of BRII-693 against clinically relevant gram-negative pathogens, supporting its potential as a next-generation macrocyclic peptide antibiotic.
2026-02-24 | Myeloid-derived interleukin-10 induced by thrombospondin-1 mediates host defense and regulates inflammation during acute bacterial lung infection
ABSTRACT Pseudomonas aeruginosa ( P. aeruginosa ) is a leading cause of hospital- and ventilator-associated pneumonia, driven by virulence factors that damage lung tissue. Neutrophils and monocytes are myeloid immune cells that play key roles in host defense during pulmonary infection against P. aeruginosa ; although if not properly regulated, their inflammatory activity can lead to severe lung injury. Thrombospondin-1 (TSP-1) is a host glycoprotein that regulates neutrophil activation in the lungs during P. aeruginosa infection, protecting the host from mortality. Here, we demonstrate that in addition to regulating the pro-inflammatory phenotype of neutrophils, during P. aeruginosa infection, TSP-1 induces IL-10 in the lung tissue of mice inoculated with this bacterium. Our data show that neutrophils and Ly6C + monocytes are major sources of lung IL-10 during the first 48 h post-infection, a cytokine that is required for host survival, host defense, and to reduce lung inflammation and injury. Further in vitro studies determined that TSP-1 induces IL-10 production in lipopolysaccharide-stimulated CD11b + Ly6G + Ly6C + cells differentiated from bone marrow precursors through a mechanism dependent on the transcription factor peroxisome proliferator-activated receptor gamma (PPARγ). Importantly, intratracheal transfer of IL-10 +/+ CD11b + Ly6G + Ly6C + cells 1 day before infection to Thbs1 −/− mice restored their ability to produce IL-10 in the lungs, improved host defense, and reduced lung inflammation and permeability upon infection. Altogether, our data show that TSP-1 induces IL-10 production in neutrophils and monocytes, enhancing host defense while reducing lung inflammation.
vaccines
2026-09-18 | Live auxotrophic vaccines contribute to protection against chronic lung infections caused by Pseudomonas aeruginosa in C57BL/6 mice.
Pseudomonas aeruginosa causes severe, often multidrug-resistant lung infections, especially in individuals with cystic fibrosis, highlighting vaccination as a promising preventive approach. This study evaluated intranasal and intradermal immunization with a D-glutamate auxotrophic P. aeruginosa strain (PAO1 ΔmurI) and two of its derivatives, one with additional D-alanine auxotrophy and another exhibiting reduced lipopolysaccharide-associated toxicity, in C57BL/6 mice using both acute and chronic lung infection models. Mice received two or three doses at various intervals, and safety was assessed through clinical and weight monitoring. A high-dose, 2-administration intranasal regimen protected against acute infection but induced transient weight loss, while a lower-dose, 3-administration regimen minimized toxicity. Immunized mice exhibited robust IL-17A production and increased IFN-γ responses. Following challenge with mucoid strains, vaccinated mice showed reduced lung bacterial loads, suggesting a partial protection against chronic infection. These findings support the potential of auxotrophic live vaccines to mitigate disease severity in patients with cystic fibrosis.
2026-08-27 | Protective-Antigen Scaffold Nanoparticle Vaccine Overcomes Carrier-Induced Suppression and Immunosenescence to Protect against Pseudomonas aeruginosa Pneumonia
Abstract Multidrug-resistant Pseudomonas aeruginosa (PA) causes severe infections, with severe burden especially in older adults. Vaccines remain effective and are urgently needed despite immunosenescence. Self-assembling nanoparticles can enhance vaccine immunogenicity, but their translational use is constrained by the useless anticarrier immunity and carrier-induced epitope suppression (CIES). Herein, we developed a protective-antigen-based nanoparticle platform in which the PA chaperonin GroEL, an intrinsically self-assembling protective antigen, serves as the scaffold for a fusion immunogen reGroEL-PO, which displays the PcrV-OprI antigen (rePO). In mice, pre-existing anti-GroEL immunity did not blunt responses but enhanced anti-rePO immunity. Mechanistically, reGroEL-PO increased antigen uptake by antigen-presenting cells, promoted dendritic-cell maturation and accelerated both humoral and cellular immunity. In addition, reGroEL-PO elicited immune responses and conferred protection in adult and aged mice. These data demonstrate reGroEL-PO as a PA vaccine candidate and illustrate a nanoparticle design that leverages protective carriers and circumvents CIES effects.
2025-07-25 | Development of a bivalent protein subunit vaccine against infection by Pseudomonas aeruginosa and Staphylococcus aureus
Pseudomonas aeruginosa (PA) and Staphylococcus aureus (SA) are members of the ESKAPE pathogens, a group of bacteria that are a threat to human health due to their ability to resist antibiotics. They are known to cause severe infections, often as co-morbidities, in individuals with conditions such as people with cystic fibrosis, diabetes, wounds, pneumonia, and critically ill patients requiring intubation leading to ventilator-associated pneumonia. Emergence of multi-drug resistance in SA and PA is making traditional antibiotic treatment ineffective and unfortunately there are no licensed vaccines to prevent MRSA or PA infections. We have demonstrated that when delivered intranasally (IN) L-PaF, a genetic fusion of the PA type III secretion system (T3SS) proteins PcrV and PopB (PaF) with LTA1, the active moiety of heat-labile enterotoxin from enterotoxigenic E. coli, protects against PA. L-PaF was formulated as a nanoemulsion (ME) to increase the protective immune response against clinically relevant PA strains in a mouse lung colonization model. With the addition NEAT2, the heme capturing domain of the SA protein IsdB, a bivalent vaccine was generated. IN administration of the bivalent formulation protected MRSA pre-exposed mice from both MRSA and PA infection. Sera from mice vaccinated with our formulation contained strong IgG titers with high levels of opsonophagocytic killing of homologous and heterologous PA and SA strains. Additionally, the bivalent L-PaF/NEAT2 formulation elicited stimulation of IL-17A and IL-2 cytokines. Because established PA and SA lung infection models with rabbits better reproduce the clinical hallmarks of severe human acute pneumonia, rabbits were immunized with the bivalent L-PaF/NEAT2 formulation. All of the vaccinated rabbits survived the challenges while the controls did not. These findings demonstrate that our L-PaF/ME/NEAT2 formulation has potential as a broad-spectrum vaccine against both SA and PA infection.
2025-07-06 | In silico development of a broad-spectrum vaccine against ESKAPE pathogens.
Antimicrobial-resistant ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter cloacae) have significantly restricted therapeutic alternatives for critical infections, consequently contributing to increase the severity and mortality of infectious illnesses that represent a significant global health challenge. Vaccination as a preventive measure can be crucial in substantially reducing bacterial infections and is potentially effective against antibiotic-resistant bacteria. This study shows the design of an epitope-based vaccine capable of neutralizing shared antigenic determinants present among the ESKAPE pathogens. The pangenome of the ESKAPE pathogens was analyzed to extract the core proteome. This approach facilitated reverse vaccinology analysis to identify antigenic proteins within this bacterial group. The study revealed similar structures in porins OmpA, OprD, and TolC, as well as the collagen-binding adhesins Acm and Cna. These proteins were then utilized to predict T-cell and B-cell epitopes, selecting those with their best physicochemical properties, antigenicity, non-allergenicity, and lack of toxicity. Additionally, epitopes located on the surface of the antigens and capable of coupling with HLA molecules were prioritized. In this computational approach, we engineered a construct incorporating the adjuvant RS09, a TLR4 agonist, and immunogenic epitopes connected by linkers. We assessed the stability of their interaction with pattern recognition receptors of the immune system through molecular docking and molecular dynamics simulations. The in silico immune simulation demonstrated that the vaccine could trigger humoral and cell-mediated immune responses. The resulting construct potentially represents an effective and safe vaccine candidate to prevent infections caused by the ESKAPE group.
2024-12-25 | Hybrid Cell Membrane-Engineered Nanocarrier for Triple-Action Strategy to Address Pseudomonas aeruginosa Infection.
Bacterial infections resistant to antimicrobial treatments, particularly those caused by Pseudomonas aeruginosa (P. aeruginosa), frequently lead to elevated mortality rates. Tackling this resistance using therapeutic combinations with varied mechanisms has shown considerable promise. In this study, a bioinspired nanocarrier is successfully designed and engineered for targeted antibiotic delivery and toxin/bacteria clearance. This is achieved by encapsulating antibiotic-loaded framework nucleic acids with hybrid cell membranes acquired from neutrophils and platelets. By coating the hybrid membrane outside the shell, nanocarriers are endowed with the function of neutrophil-like chemotaxis and platelet-like bacteria adhesion to achieve the first stage of inflammation targeting. Based on the specific binding of bacteria toxin to the hybrid membrane, the release of antibiotic-loaded framework nucleic acids is triggered by toxin-mediated membrane lysis to fulfill the second stage of toxin neutralization and bacteria killing. Meanwhile, the immunomodulation potential of framework nucleic acids enables nanocarriers to accomplish the third stage of reversing the immunosuppressive microenvironment. In mouse models of acute and chronic P. aeruginosa pneumonia, the nanocarriers can reduce bacterial burden at a low dosage and decrease mortality with negligible toxicity. In sum, these findings have illustrated the remarkable capability of nanocarriers in treating recalcitrant bacterial infections.
gene therapies
2026-09-30 | A broad-host-range inhalable phage cocktail for treatment of multidrug-resistant Pseudomonas aeruginosa pulmonary infections.
The growing threat of multidrug-resistant (MDR) Pseudomonas aeruginosa (P. aeruginosa) has created an urgent need for novel therapeutic strategies to combat refractory lung infections. The limited efficacy of traditional antibiotics against this pathogen highlights the necessity of developing alternative treatments. Our study aims to develop a broad-spectrum bacteriophage cocktail suitable for nebulization and to evaluate its antibacterial efficacy and safety in respiratory infections caused by MDR P. aeruginosa. We constructed a seven-phage cocktail by selecting phages with complementary host ranges, strong lytic activity, and different receptor targets. The antimicrobial and anti-biofilm activity of the cocktail was assessed in vitro against clinical MDR P. aeruginosa isolates. The therapeutic efficacy and safety were further investigated in a murine pneumonia model following nebulized administration. The phage cocktail demonstrated lytic activity against nearly 90% of 152 clinical P. aeruginosa isolates, indicating broad coverage. Compared to single phages or antibiotics, the cocktail showed superior activity in both inhibiting and disrupting biofilms. In the murine pneumonia model, nebulized phage therapy improved survival, reduced bacterial burdens in lung and liver, and alleviated infection-related histopathological damage. Safety assessment revealed no obvious hematological, biochemical or histopathological abnormalities in both acute and long-term administration. High-dose nebulized administration of this phage cocktail reduced bacterial burden and showed favorable tolerability in a murine model of MDR P. aeruginosa pneumonia. These findings provide preclinical evidence supporting further evaluation of inhaled phage cocktails as a potential therapeutic strategy for refractory respiratory infections.
2026-06-27 | Inhalable bacteriophage endolysins: a novel therapeutic strategy for drug-resistant bacterial pulmonary infections - a comprehensive review.
Pulmonary infections caused by multidrug-resistant (MDR) bacteria pose a severe global health threat with high mortality rates, especially in hospital-acquired pneumonia. The stagnation of new antibiotic development underscores the urgent need for alternative therapeutics. This review summarizes recent advances in the application of bacteriophage endolysins against major MDR respiratory pathogens, including Staphylococcus aureus, Streptococcus pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae. We focus on their mechanisms of action, synergistic effects with antibiotics, and efficacy against biofilms. Endolysins demonstrate potent and species-specific lytic activity against a broad spectrum of MDR bacteria. A key advantage is their low propensity for inducing resistance. Critically, when administered via optimized inhalation delivery systems, endolysins can achieve high local concentrations in the lungs - though this depends on factors such as the aerosol device, formulation properties and patient-related variables - effectively eradicating pathogens in animal models of pneumonia with minimal systemic toxicity. This direct pulmonary delivery approach bypasses many challenges associated with systemic administration and enhances therapeutic outcomes. Endolysins represent a promising paradigm shift in combating drug-resistant bacterial pulmonary infections. Their rapid lytic activity, synergy with conventional antibiotics, and suitability for inhalable formulation position them as a potent adjunct or alternative therapy. While challenges in stabilization and large-scale production remain, advancing inhalation delivery systems for endolysins holds immense potential to holds immense potential to revolutionize the treatment of recalcitrant respiratory infections.
2026-03-27 | Mapping the clinical use of inhaled bacteriophages in respiratory infections caused by multidrug-resistant pathogens: a scoping review.
Inhaled bacteriophage therapy is an emerging adjunctive strategy for treating lower respiratory tract infections caused by multidrug-resistant (MDR) pathogens. However, the clinical evidence base remains fragmented. We conducted a scoping review to map the current landscape of human studies using nebulized, aerosolized, or dry-powder phage therapy for pulmonary infections. We systematically searched PubMed, Scopus, Web of Science, and ClinicalTrials.gov for clinical studies published up to 1 June 2025. Eligible studies included clinical trials, cohort studies, and case reports/series reporting at least one dose of inhaled lytic phage for bacterial respiratory infections. Screening followed PRISMA-ScR guidelines. Key data were extracted on patient characteristics, pathogens, phage preparations, delivery methods, safety, and outcomes. Of 507 records identified, 31 studies met inclusion criteria: six clinical trials and 25 case reports or series. Target infections included ventilator-associated pneumonia, cystic fibrosis exacerbations, and chronic bronchiectasis, primarily due to Pseudomonas aeruginosa, Acinetobacter baumannii, or Klebsiella pneumoniae. Delivery methods varied widely, including nebulizers, dry-powder inhalers, and endotracheal instillation. Most studies reported clinical or microbiological improvement without major adverse events, though few used standardized outcome measures. Inhaled phage therapy has shown promise in compassionate and investigational settings for MDR respiratory infections. Despite heterogeneity in delivery methods and outcome reporting, preliminary data suggests feasibility and safety. Standardized protocols and controlled trials are needed to define its role in pulmonary antimicrobial therapy.
2026-02-22 | <b>Evaluating a Novel Bacteriophage Cocktail for Eradicating Pseudomonas aeruginosa Biofilms in Ventilator-Associated Pneumonia</b>
Background: Ventilator-associated pneumonia caused by Pseudomonas aeruginosa remains difficult to treat because of multidrug resistance and biofilm formation, which reduce antibiotic penetration and contribute to persistent infection in mechanically ventilated patients. Objective: To evaluate the efficacy of adjunctive nebulized bacteriophage cocktail therapy in reducing P. aeruginosa biofilm burden and improving microbiological and clinical outcomes in ventilator-associated pneumonia. Methods: A parallel-group randomized controlled trial was conducted in tertiary care intensive care units over five months. Seventy-two mechanically ventilated adults with microbiologically confirmed P. aeruginosa ventilator-associated pneumonia and evidence of biofilm formation were randomized to receive either standard culture-guided antibiotic therapy plus nebulized bacteriophage cocktail twice daily for 14 days or standard care alone. Primary outcomes were biofilm biomass reduction and microbiological clearance; secondary outcomes included duration of mechanical ventilation, Clinical Pulmonary Infection Score, and intensive care unit stay. Results: The final analyzed cohort included 63 participants. Day-14 biofilm biomass was significantly lower in the intervention group than in controls (0.62 ± 0.18 vs 0.94 ± 0.22 OD units; p<0.001). Culture negativity was higher with bacteriophage therapy (75.0% vs 45.2%; p=0.01). The intervention group also had shorter mechanical ventilation duration, lower day-14 Clinical Pulmonary Infection Score, and reduced intensive care unit stay (p<0.05 for all). Conclusion: Adjunctive nebulized bacteriophage cocktail therapy improved biofilm reduction, microbiological clearance, and short-term clinical outcomes in P. aeruginosa ventilator-associated pneumonia.
2025-12-16 | Navigating the Crisis of Multidrug-Resistant Infections in Infants to Teenagers: Regional Variability and Global Solutions
Superbacteria, or multidrug-resistant (MDR) microorganisms, pose a major global health threat, particularly in regions such as South Asia and sub-Saharan Africa. Bacteria, such as Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa, are resistant to multiple antibiotics, making infections more difficult to treat. These resistant infections cause millions of deaths annually, with vulnerable groups, such as neonates and children, being particularly at risk. The overuse of antibiotics in medicine and livestock, along with weak healthcare systems, accelerates the spread of antibiotic resistance, especially in countries such as India, China, and Pakistan. Common resistant infections include urinary tract infections, neonatal sepsis, and ventilator-associated pneumonia (VAP). Resistance to antibiotics, such as carbapenems and third-generation cephalosporins, along with the rise of ESBL-producing bacteria, complicates treatment, particularly in neonatal intensive care units (NICUs). This paper reviews global data on superbacteria, focusing on neonatal and pediatric populations, highlighting the need for better diagnostics, novel treatments (e.g., phage therapy), antimicrobial stewardship, infection control, and global cooperation to combat the growing threat of resistance.
other
2026-09-23 | The interface of biofilm and immune system for Gram-negative ESKAPE pathogens.
The ESKAPE group of pathogens comprises Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp., which are capable of developing profound biofilms while infecting host tissues and medical devices. In addition to acting as a barrier to antimicrobial treatments and as a niche for the transmission of antibiotic resistance genes, biofilm-associated extracellular polymeric substances and metabolites modulate innate and adaptive immune responses. With the rise of emerging resistance against last-resort antibiotics, divulging the cross-talk between ESKAPE biofilms and the host immune system is essential for designing therapies aimed at immunoactivation. Compared with their Gram-positive ESKAPE counterparts, limited therapeutics coupled with higher mortality-associated phenotypes make Gram-negative ESKAPE pathogens an urgent priority for immediate action. The ultimate goals for strategizing such interventions are to disrupt biofilm integrity, restore immune efficacy, and improve clinical outcomes against multi- or pan-drug-resistant pathogens. Against this backdrop, this review highlights the alteration of the host immune system and the modifications in innate and adaptive immune responses caused by Gram-negative ESKAPE pathogens. In addition, the possibility of success of immunomodulation-based strategies in combating bacterial biofilms and accentuating the activity of known antimicrobials is discussed objectively.
2026-08-28 | Broad-Spectrum Protective Efficacy of a Fully Human Antibody Cocktail Targeting PcrV, ETA, and PA0833 Against Pseudomonas aeruginosa Infection.
Pseudomonas aeruginosa (P. aeruginosa) pose a global health threat, with carbapenem-resistant strains in particular posing a grave threat due to high mortality rates and limited treatment options for antibiotic-refractory infections. To address the inherent limitations of single-target therapies, this study developed a multi-target fully human monoclonal antibody (mAb) cocktail targeting three core virulence factors: a key component of the type III secretion system, exotoxin A, and an outer membrane protein. Using a fully human transgenic mouse platform, we generated and characterized three high-affinity mAbs targeting PcrV (U0151, Kd = 2.69 nM), ETA (U0462, Kd = 1.75 nM), and PA0833 (U0057, Kd = 0.34 nM). Functional assays confirmed robust target-specific activities, including neutralization of PcrV-mediated hemolysis, inhibition of ETA-induced cytotoxicity, and enhancement of cell-mediated bacterial clearance. In mouse models of systemic infection and acute pneumonia caused by PAO1, a significant enhancement in efficacy was observed when three types of antibodies were used in combination, increasing protective rates to 78% and 88%, respectively, whereas monotherapies achieved protective rates of no more than 38%. Combined treatment also reduced bacterial burden, alleviated tissue damage, and suppressed excessive neutrophil infiltration. Furthermore, it showed immune protection against several clinical isolates of P. aeruginosa, including carbapenem-resistant strains, within these limits, the data support the three-antibody combination as a candidate adjunctive immunotherapy for multidrug-resistant P. aeruginosa infection.
2026-06-17 | Engineering low-endotoxin lipid A in a double auxotroph Pseudomonas aeruginosa to develop safer whole-cell vaccines.
Pseudomonas aeruginosa is a highly adaptable Gram-negative bacterium causing severe respiratory infections, particularly in vulnerable populations. The rise of antimicrobial resistance highlights the urgent need for effective vaccines. We previously developed a live-attenuated vaccine candidate, PAO1 ΔmurI Δalr ΔdadX, a genetically stable double auxotrophic strain that exhibited dose-dependent reactogenicity upon intranasal administration in mice, likely due to lipid A component of lipopolysaccharide (LPS). To reduce LPS-associated toxicity while preserving immunogenicity, we engineered novel strains by inactivating genes involved in lipid A biosynthesis (htrB1, htrB2) or modification (pagP, pagL). Lipid A structural modifications were confirmed by MALDI-TOF MS. Mutants were evaluated for Toll-like receptor 4 (TLR4) activation, virulence attenuation, and their ability to induce immune responses and protection in an acute pneumonia model. All engineered strains displayed modified lipid A structures. Mutations in htrB1 and htrB2 reduced TLR4 activation and significantly attenuated virulence following intraperitoneal challenge in mice. Inactivation of pagL resulted in minimal attenuation, whereas pagP inactivation led to marked attenuation without altering TLR4 activation. In the acute pneumonia model, all mutants elicited robust systemic and mucosal immune responses, and conferred strong protection, despite transient weight loss following intranasal administration. Targeted lipid A modification represents an effective strategy to reduce in vitro reactogenicity while preserving immunogenicity in live-attenuated P. aeruginosa vaccine candidates. Although further optimization may minimize residual in vivo effects, these findings support the potential of engineered strains as vaccine candidates for preventing respiratory infections caused by P. aeruginosa.
2026-06-17 | Engineered antibodies bypass bacterial immune evasion to drive complement-mediated protection against lethal infections.
The expanding global crisis of bacterial infections caused by antimicrobial-resistant pathogens has resulted in an urgent need for therapeutics. Previous efforts to target pathogen surface antigens with monoclonal antibodies (mAbs) have sought to activate the complement system, primarily through the antibody-dependent classical pathway. However, most mAbs have induced insufficient complement activation because pathogen evasion strategies disrupt the complex spatiotemporal requirements for activation of the classical pathway initiation complex C1. To address this, we developed a targeted complement activation therapy (T-CAT), which uses antibodies furnished with the enzymatic capability to initiate complement activation directly on the bacterial surface without involvement of the classical pathway initiation complex. We found that T-CAT mAbs directed against bacterial surface antigens can overcome the strategies that pathogens evolved to escape from classical pathway-mediated clearance by the immune system. We further demonstrated that T-CAT mAbs could safely and effectively be used to treat infectious disease in experimental murine models of sepsis and pneumonia caused by Klebsiella pneumoniae, Pseudomonas aeruginosa, Streptococcus pneumoniae, and Neisseria meningitidis. Together, these data highlight the potential for T-CAT as a next-generation mAb platform with broad applicability against diverse microbial species, including multidrug-resistant pathogens, without promoting drug resistance.
2026-06-12 | AZinc-Coordinated Glycopolymer for Inhibiting BacterialToxins in Management of Acute Pneumonia
Bacterial toxins play a critical role in infections by compromising host defenses, causing host cell death, and inducing excessive immune activation, ultimately leading to severe tissue damage and increased mortality. To combat both the pathogen and its associated toxins, this study developed a bacteria-targeting zinc-coordinated glycopolymer designed to deliver antisense oligonucleotides (ASOs) and absorb lipopolysaccharides (LPS). The functional polymer enhances Pseudomonas aeruginosa internalization efficiency through galactose-mediated bacterial surface interaction. By delivering multiple ASOs, the nanoparticle enables the dual suppression of bacterial growth and quorum sensing, exhibiting potent antibacterial activity. Furthermore, zinc ions coordinated within the glycopolymer impart the ability to bind and adsorb LPS, thereby mitigating the toxin-induced damage to host cells. In a murine model of acute pneumonia, this approach significantly improved survival rates and reduced pro-inflammatory cytokine levels. Consequently, pulmonary inflammation was suppressed, bacterial toxin-induced damage was alleviated, and tissue integrity was preserved. This synergistic strategy of combined sterilization and toxin neutralization offers a novel and synergistic therapeutic approach to combating bacterial infections.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
8 orphan drug designations for Pneumonia caused by Pseudomonas aeruginosa infection.
8 orphan drug designations for Pneumonia caused by Pseudomonas aeruginosa infection.
Drug | Therapy type | Orphan designation | Clinical trial status | Sponsor |
|---|---|---|---|---|
Human monoclonal antibody IgM directed against Pseudomonas aeruginosa serotype O1 O-polysaccharide [KBPA 104] | antibodies | EMA | Envestia Limited | |
human monoclonal antibody directed against serotype O1 Pseudomonas aeruginosa | antibodies | FDA | Kenta Biotech Limited | |
Tobramycin [Vantobra] | small molecules | EMA | Pari Pharma GmbH | |
Human monoclonal antibody directed against serotype 011 Pseudomonas aeruginosa | antibodies | FDA | Kenta Biotech Limited | |
Human monoclonal antibody against Pseudomonas aeruginosa serotype O11 | antibodies | EMA | Marcello Menapace | |
Tobramycin [Fluidosomes Tobramycin] | small molecules | EMA | [INACTIVE] Axentis Phama Limited | |
Tobramycin [Tobi Podhaler] | small molecules | EMA | Viatris Healthcare Limited | |
Pseudomonas aeruginosa octavalent conjugated vaccine [Aerugen] | vaccines | EMA | — | Recordati Rare Diseases |
“Terminated” – programs with discontinued clinical trials, or with no updates reported for 5 years after completion or 12 years after the last trial started.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.